ArticleScientific reports2025
Clinical significance and potential molecular mechanisms of SYT15 expression in lung adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Increasing evidence suggests that the synaptotagmin (SYT) family is associated with the development of multiple types of cancer, yet research on SYT15 remains limited. The aim of this study was to elucidate the clinical significance and possible molecular mechanisms of SYT15 expression in lung adenocarcinoma (LUAD). The expression, clinical value, cellular function and possible molecular mechanisms of SYT15 in LUAD were evaluated by using bioinformatics analysis combined with cellular experiments. In LUAD, SYT15 expression was downregulated. Notably, this reduced expression was negatively associated with patient survival but positively correlated with immune cell infiltration in the tumor microenvironment. Furthermore, SYT15 expression correlated with three key aspects: sensitivity to 20 distinct drugs, the expression of immune checkpoint genes (ICGs), and the efficacy of immunotherapy. SYT15 was most highly expressed in Mono/Macro, CD8Tex, and CD8T cells within LUAD tissues. Cellular experiments confirmed that SYT15 overexpression reduced the malignant phenotype of A549 and H1975 cells. RNA sequencing results showed that the PI3K/AKT signaling pathway was significantly enriched after overexpression of SYT15 in A549 cells, and qPCR and WB experiments confirmed significant downregulation of genes related to this pathway.. Further experiments confirmed that PI3K agonist 740Y-P reversed the regulatory effects of SYT15 overexpression on A549 cell malignant phenotype and the PI3K/Akt signaling pathway. In LUAD, SYT15 acts as a tumor suppressor by potentially regulating immune cell infiltration in the tumor microenvironment and inhibiting the expression of key PI3K/AKT pathway genes in A549 cells. Consequently, it holds promise as a novel prognostic marker and potential therapeutic target..
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.